Primary Category:
Treatment Protocols
Disease Category:
Genitourinary
Status:
Open
A Phase III Randomized Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy
S1937 , Arms 1 & 3 are reopened with the implementation of Revision 3 effective Feburary 20, 2024.
S1937, Arm 2 is closed to accrual, effective February 15, 2024.
Eligible for screening study DCP 001
NCT#04579224
